The 13 analysts offering 12-month price forecasts for Intra-Cellular Therapies Inc have a median target of 70.00, with a high estimate of 90.00 and a low estimate of 57.00. The median estimate represents a +33.21% increase from the last price of 52.55.
The current consensus among 14 polled investment analysts is to Buy stock in Intra-Cellular Therapies Inc. This rating has held steady since June, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.80
Reporting Date Nov 09
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.